These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28851363)

  • 1. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
    Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
    Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate Cancer.
    Jiménez-Vacas JM; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; Ruiz-Pino F; Guler I; Camargo A; Anglada FJ; Carrasco-Valiente J; Tena-Sempere M; Sarmento-Cabral A; Castaño JP; Gahete MD; Luque RM
    J Clin Endocrinol Metab; 2021 Nov; 106(12):e4956-e4968. PubMed ID: 34255835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters.
    Luque RM; Sampedro-Nuñez M; Gahete MD; Ramos-Levi A; Ibáñez-Costa A; Rivero-Cortés E; Serrano-Somavilla A; Adrados M; Culler MD; Castaño JP; Marazuela M
    Oncotarget; 2015 Aug; 6(23):19619-33. PubMed ID: 26124083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
    Hormaechea-Agulla D; Jiménez-Vacas JM; Gómez-Gómez E; L-López F; Carrasco-Valiente J; Valero-Rosa J; Moreno MM; Sánchez-Sánchez R; Ortega-Salas R; Gracia-Navarro F; Culler MD; Ibáñez-Costa A; Gahete MD; Requena MJ; Castaño JP; Luque RM
    FASEB J; 2017 Nov; 31(11):4682-4696. PubMed ID: 28705809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines.
    Rincón-Fernández D; Culler MD; Tsomaia N; Moreno-Bueno G; Luque RM; Gahete MD; Castaño JP
    Carcinogenesis; 2018 Mar; 39(3):447-457. PubMed ID: 29272342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features.
    Ibáñez-Costa A; Gahete MD; Rivero-Cortés E; Rincón-Fernández D; Nelson R; Beltrán M; de la Riva A; Japón MA; Venegas-Moreno E; Gálvez MÁ; García-Arnés JA; Soto-Moreno A; Morgan J; Tsomaia N; Culler MD; Dieguez C; Castaño JP; Luque RM
    Sci Rep; 2015 Mar; 5():8714. PubMed ID: 25737012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance.
    Gahete MD; Córdoba-Chacón J; Hergueta-Redondo M; Martínez-Fuentes AJ; Kineman RD; Moreno-Bueno G; Luque RM; Castaño JP
    PLoS One; 2011; 6(8):e23302. PubMed ID: 21829727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
    Pedraza-Arévalo S; Hormaechea-Agulla D; Gómez-Gómez E; Requena MJ; Selth LA; Gahete MD; Castaño JP; Luque RM
    Prostate; 2017 Nov; 77(15):1499-1511. PubMed ID: 28905400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker.
    Hormaechea-Agulla D; Gómez-Gómez E; Ibáñez-Costa A; Carrasco-Valiente J; Rivero-Cortés E; L-López F; Pedraza-Arevalo S; Valero-Rosa J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Gahete MD; López-Miranda J; Requena MJ; Castaño JP; Luque RM
    Cancer Lett; 2016 Dec; 383(1):125-134. PubMed ID: 27693462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.
    Herrera-Martínez AD; Gahete MD; Sánchez-Sánchez R; Alors-Perez E; Pedraza-Arevalo S; Serrano-Blanch R; Martínez-Fuentes AJ; Gálvez-Moreno MA; Castaño JP; Luque RM
    Clin Transl Gastroenterol; 2018 Oct; 9(10):196. PubMed ID: 30297816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ghrelin receptor as a novel imaging target for prostatic neoplasms.
    Lu C; McFarland MS; Nesbitt RL; Williams AK; Chan S; Gomez-Lemus J; Autran-Gomez AM; Al-Zahrani A; Chin JL; Izawa JI; Luyt LG; Lewis JD
    Prostate; 2012 Jun; 72(8):825-33. PubMed ID: 21919027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
    Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
    Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Proteome of Primary Prostate Cancer.
    Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
    Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer.
    Sáez-Martínez P; Jiménez-Vacas JM; León-González AJ; Herrero-Aguayo V; Montero Hidalgo AJ; Gómez-Gómez E; Sánchez-Sánchez R; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32498336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
    Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.
    Xiao Y; Yuan Y; Zhang Y; Li J; Liu Z; Zhang X; Sheng Z; Xu T; Wang X
    Clin Transl Oncol; 2015 Jun; 17(6):431-7. PubMed ID: 25387568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.
    Gómez-Gómez E; Jiménez-Vacas JM; Carrasco-Valiente J; Herrero-Aguayo V; Blanca-Pedregosa AM; León-González AJ; Valero-Rosa J; Fernández-Rueda JL; González-Serrano T; López-Miranda J; Gahete MD; Castaño JP; Requena-Tapia MJ; Luque RM
    J Cell Mol Med; 2018 Nov; 22(11):5688-5697. PubMed ID: 30256519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.